John Hession Speaking on CFIUS and Cross-Border Biotech Transactions

M0846571At the April 9th MassBio event Cross-Border Biotech Transactions: CFIUS and Other Risks, corporate partner John Hession will speak on the risks that early-stage biotech companies face when pursuing strategic alliances with foreign partners or investors. The discussion will center around the Committee on Foreign Investment in the United States’ (CFIUS) expansion of its regulation of cross-border transactions, and the consequences that management of U.S. biotech companies need to be aware of.

Further details and registration information can be found on the MassBio website.